Joel Palefsky, MD

Joel Palefsky
Global Health Sciences Faculty Affiliate

Phone: 415-476-1574
UCSF Box: 0654
Email: [email protected]
UCSF Profile

Project Sponsor Location(s) Topics Start End
Natural History of Anal Neoplasia in HIV-Infected Men NIH National Cancer Institute United States HIV/AIDS
HPV and Cervix Neoplasia in a Large, Long Term HIV+ Cohort Albert Einstein College of Medicine United States HIV/AIDS, Aging
Women and Infants Transmission Study - Human Papillomavirus Protocol Baylor College of Medicine United States Infectious Disease, HIV/AIDS, Cancer/Oncology, Women's Health
HPV and AIDS Malignancies Clinical Trials Consortium (AMC) University of Alabama System United States HIV/AIDS, Cancer/Oncology
SMART Anal Dysplasia Sub-Study Social & Scientific Systems, Inc. United States HIV/AIDS, Opportunistic Infection, Cancer/Oncology
Doris Duke Clinical Research Fellowship (CRF) Program for Medical Students Doris Duke Charitable Foundation Kenya; Tanzania; India; Peru Residencies, Fellowships, and Postdoctoral Training
UCSF Predoctoral Clinical Research Training Program NIH National Institute of Child Health and Human Development United States Training and Capacity Building
Anal HPV Infection and ASIL in HIV+ and HIV- Women NIH National Cancer Institute United States HIV/AIDS, Women's Health
Anal Human Papillomavirus (HPV) in Methamphetamine (MA) Using and Non-Using Men Who Have Sex with Men (MSM) in Los Angeles University of California Los Angeles (UCLA) United States Infectious Disease, Cancer/Oncology, Substance Abuse, Risk Reduction and Prevention
California Division Special Research Scholar Grant in HIV-Related Cancers American Cancer Society, Inc. United States HIV/AIDS, Cancer/Oncology
Doris Duke Clinical Research Fellowship (CRF) Program for Medical Students Doris Duke Charitable Foundation Kenya; Uganda; Tanzania; India Residencies, Fellowships, and Postdoctoral Training
Doris Duke Charitable Foundation International Clinical Research Fellowship Program Doris Duke Charitable Foundation Kenya; Uganda; Tanzania; Zimbabwe; Ghana; Cambodia; Thailand; Nicaragua HIV/AIDS, Tuberculosis, Malaria, Cancer/Oncology, Cardiovascular Disease, Oral Health, Neurology and Mental Health, Women's Health, Pediatrics, Newborn and Infant Health, Immigration and Migration, Training and Capacity Building, Residencies, Fellowships, and Postdoctoral Training
A Master Agreement: HPV Testing of Samples from the AIDS Malignancy Consortium EMMES Corporation India HIV/AIDS, Cancer/Oncology, Women's Health
Cidofovir for Perianal Dysplasia in HIV Patients Boston Medical Center Corporation United States HIV/AIDS, Cancer/Oncology
HIV Facilitated Paracellular Penetration of HPV across Mucosal Epithelium University of Pennsylvania United States HIV/AIDS
Marshalling Science for Global Health: A Bilateral Workshop Canada-California Strategic Innovation Partnership Canada Health Systems Strengthening, Training and Capacity Building
The Impact of Anogenital Human Papillomavirus in the Transmission of HIV in Urban Brazil: Phase II Study Merck and Co., Inc. Brazil Infectious Disease, Pharmacology and Drug Treatment
Determinants of Participation in an Anal Cancer Prevention Trial NIH National Cancer Institute United States Cancer/Oncology
Epidemiologic Effects of ART on HIV-related Anal Cancer and Anal Dysplasia Baylor College of Medicine United States Infectious Disease, HIV/AIDS, Cancer/Oncology
A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females Brigham and Women's Hospital United States HIV/AIDS
Anal Cytology/HPV Testing Study Women and Infants Hospital of Rhode Island United States Infectious Disease, Cancer/Oncology, Systematic Reviews and Guideline Development
Doris Duke Clinical Research Fellowship Renewal Doris Duke Charitable Foundation Kenya; Uganda; Tanzania; Zimbabwe; India; Cambodia Training and Capacity Building
APTIMA HPV Clinical Study on Anal Specimens from Men Who Have Sex with Men (MSM) Gen-Probe Incorporated United States Sexually Transmitted Infections (STIs)
A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26- Year-Old Men and 16- to 26- Year-Old Women Merck and Co., Inc. South Africa; Malaysia; Thailand; Israel; Turkey; Denmark; Germany; Norway; Poland; Spain; Sweden; Mexico; Colombia; Peru; Canada Women's Health
HPV Cervical Neoplasia in a Long-Term HIV+ Cohort Albert Einstein College of Medicine United States Sexually Transmitted Infections (STIs), Cancer/Oncology, Women's Health
HPV Testing of Samples from the AIDS Malignancy Consortium EMMES Corporation India HIV/AIDS
HPV-Related Neoplasia among HIV-Seropositive Indian Men Who Have Sex With Men NIH National Cancer Institute India HIV/AIDS, Cancer/Oncology
Incidence of HIV among Indian Men Who Have Sex with Men NIH National Cancer Institute India HIV/AIDS, Epidemiology and Surveillance
Thai Red Cross S&S, HN177 HIV-NAT, The Thai Red Cross AIDS Res Ctr Thailand Infectious Disease, Sexually Transmitted Infections (STIs), Cancer/Oncology
HPV Testing Contract for UPR NIDCR-funded R21, "Detection of HPV infection in the oral cavity of Hispanics with and without periodontal disease" University of Puerto Rico Puerto Rico Infectious Disease, Oral Health
HPV testing of samples from the AIDS Malignancy Consortium University of California Los Angeles (UCLA) Kenya; Uganda; India; Brazil HIV/AIDS, Opportunistic Infection, Cancer/Oncology
Administrative Supplements to Cancer Centers Support Grants to Stimulate Collaborative HIV Malignancy Research in Low and Middle Income Countries University of Maryland, Baltimore Uganda HIV/AIDS, Cancer/Oncology, Women's Health
Merck Men's Efficacy Study, V501 Merck and Co., Inc. United States Infectious Disease
HIV/HPV cancer prevention treatment and pathogenesis: Rwanda /Einstein Consortium Albert Einstein College of Medicine Rwanda HIV/AIDS, Opportunistic Infection, Cancer/Oncology
International Clinical Research Fellowships for Medical Students Doris Duke Charitable Foundation Kenya; Uganda; Tanzania; Zimbabwe; India; Cambodia Residencies, Fellowships, and Postdoctoral Training
ANCHOR (Anal Cancer/HSIL Outcomes Research) Study (AMC Supplement Administrative Core) University of California Los Angeles (UCLA) United States Cancer/Oncology
Thai Red Cross S&S, HPV TA008 HIV-NAT, The Thai Red Cross AIDS Res Ctr Thailand Infectious Disease, Sexually Transmitted Infections (STIs), Cancer/Oncology, Pharmacology and Drug Treatment
(PQ5) Role of HIV-associated cellular miRNAs in HPV 16-induced pathogenesis NIH National Cancer Institute United States Infectious Disease, Sexually Transmitted Infections (STIs), Cancer/Oncology
The Microbiome and Anal Cancer Pathogenesis in HIV-infected Men who have Sex with Men NIH National Cancer Institute United States Infectious Disease, HIV/AIDS, Cancer/Oncology
New therapeutic HPV vaccines for HIV-infected men and women NIH National Cancer Institute United States Genetics
Next Generation of HPV and Cervical Cancer Research in HIV+ Women Albert Einstein College of Medicine United States HIV/AIDS, Infectious Disease, Sexually Transmitted Infections (STIs), Cancer/Oncology
Anal Dysplasia SCC Supplement for P30 Cancer Support Grant to Stimulate HIV/AIDS Cancer Research Projects NCI-designated Cancer Centers Washington University in St. Louis United States HIV/AIDS, Infectious Disease, Cancer/Oncology
A Phase I, Dose Escalation Study To Establish Safety of Leukocyte Interleukin, Injection [Multikine] for Treatment of Perianal Condylomata In Adult Men and Women Who Are HIV/HPV Co-infected United States HIV/AIDS, Opportunistic Infection, Cancer/Oncology
GINI: Gardasil Immunogenicity with Needle-free Injection-Safety and Immunogenicity of Gardasil using IM and ID needle-free injection delivery Merck and Co., Inc. Thailand Sexually Transmitted Infections (STIs), Cancer/Oncology
(PQ4) Anal HPV infection and anal HSIL among HIV-infected MSM aged 50+ years NIH National Cancer Institute United States Infectious Disease, HIV/AIDS, Cancer/Oncology
AMC-103: A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals Inovio Pharmaceuticals, Inc. United States Infectious Disease, Sexually Transmitted Infections (STIs)